Adding Abiraterone to Standard Therapy Helps People With Metastatic Prostate Cancer to Live Longer

Adding the drug abiraterone to standard hormone therapy helps people with prostate cancer that has spread to other parts of the body to live longer. Results from the STAMPEDE trial were presented at the European Society for Medical Oncology Congress in Paris last week. For more on this, please click on the following link to the UCL News feed:


Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.